AXIM Biotechnologies, Inc. Aktie Other OTC
Aktien
A2DF26
US05463V1008
AXIM
Biotechnologie
Umsatz 2022 | 8875 8159.68 | Umsatz 2023 | 39’518 36’332.85 | Marktwert | 4.52 Mio. 4.15 Mio. |
---|---|---|---|---|---|
Nettoergebnis 2022 | -6 Mio. -5.52 Mio. | Nettoergebnis 2023 | -8 Mio. -7.36 Mio. | EV / Sales 2022 | 1’218 x |
Nettoschuld 2022 | 5.64 Mio. 5.19 Mio. | Nettoschuld 2023 | 5.74 Mio. 5.28 Mio. | EV / Sales 2023 | 259 x |
KGV 2022 |
-0.69
x | KGV 2023 |
-0.48
x | Beschäftigte | - |
Rendite 2022 * |
-
| Rendite 2023 |
-
| Streubesitz | 71.61% |
Manager | Titel | Alter | Seit |
---|---|---|---|
John Huemoeller
CEO | Chief Executive Officer | 68 | - |
Robert Malasek
DFI | Director of Finance/CFO | 55 | 29.06.16 |
Kurt Phinney
COO | Chief Operating Officer | - | 23.05.23 |
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
John Huemoeller
CEO | Chief Executive Officer | 68 | - |
Timothy Scott
BRD | Director/Board Member | 71 | 18.05.17 |
Director/Board Member | 76 | 18.05.17 |
% 1. Jan. | Kap. | |
---|---|---|
+0.17% | 42.86 Mrd. | |
+10.92% | 42.74 Mrd. | |
+44.30% | 41.36 Mrd. | |
-6.20% | 27.68 Mrd. | |
+5.23% | 25.15 Mrd. | |
-24.79% | 18.63 Mrd. | |
+26.69% | 12.37 Mrd. | |
-3.13% | 11.92 Mrd. | |
+6.57% | 11.21 Mrd. |